Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M74,698Revenue $M6,494Net Margin (%)20.8Z-Score6.0
Enterprise Value $M75,474EPS $1.7Operating Margin %27.1F-Score7
P/E(ttm))54.2Cash Flow Per Share $4.4Pre-tax Margin (%)24.2Higher ROA y-yN
Price/Book15.510-y EBITDA Growth Rate %0Quick Ratio5.2Cash flow > EarningsY
Price/Sales11.35-y EBITDA Growth Rate %22.2Current Ratio5.4Lower Leverage y-yN
Price/Cash Flow17.9y-y EBITDA Growth Rate %2.8ROA % (ttm)10.9Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)27.9Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M801ROI % (ttm)17.8Gross Margin Increase y-yY

Gurus Latest Trades with CELG

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CELGGeorge Soros 2014-06-30 Buy 0.45%$68.45 - $86.8
($75.89)
$ 93.9424%New holding, 688000 sh.688,000
CELGJoel Greenblatt 2014-06-30 Buy 0.07%$68.45 - $86.8
($75.89)
$ 93.9424%New holding, 63980 sh.63,980
CELGRonald Muhlenkamp 2014-06-30 Reduce-1.91%$68.45 - $86.8
($75.89)
$ 93.9424%Reduce -51.74%144,140
CELGRay Dalio 2014-06-30 Sold Out -0.08%$68.45 - $86.8
($75.89)
$ 93.9424%Sold Out0
CELGJohn Burbank 2014-06-30 Sold Out -0.01%$68.45 - $86.8
($75.89)
$ 93.9424%Sold Out0
CELGRay Dalio 2014-03-31 Add0.07%$69.65 - $85.97
($79.51)
$ 93.9418%Add 962.69%142,400
CELGJohn Burbank 2014-03-31 Buy 0.01%$69.65 - $85.97
($79.51)
$ 93.9418%New holding, 1670 sh.3,340
CELGJohn Keeley 2014-03-31 Sold Out $69.65 - $85.97
($79.51)
$ 93.9418%Sold Out0
CELGRonald Muhlenkamp 2013-12-31 Add0.12%$72.25 - $85.39
($79.05)
$ 93.9419%Add 2.87%294,850
CELGRay Dalio 2013-12-31 Buy 0.01%$72.25 - $85.39
($79.05)
$ 93.9419%New holding, 6700 sh.13,400
CELGMario Gabelli 2013-09-30 Add$60.13 - $77.31
($70.14)
$ 93.9434%Add 29.5%20,940
CELGJohn Keeley 2013-09-30 Buy $60.13 - $77.31
($70.14)
$ 93.9434%New holding, 1320 sh.2,640
CELGJohn Hussman 2013-09-30 Sold Out -0.31%$60.13 - $77.31
($70.14)
$ 93.9434%Sold Out0
CELGRonald Muhlenkamp 2013-06-30 Reduce-0.96%$56.1 - $65.09
($60.18)
$ 93.9456%Reduce -21.92%285,770
CELGJoel Greenblatt 2013-06-30 Sold Out -0.01%$56.1 - $65.09
($60.18)
$ 93.9456%Sold Out0
CELGJohn Hussman 2013-03-31 Reduce-0.71%$39.24 - $57.96
($50.79)
$ 93.9485%Reduce -85.25%118,000
CELGJoel Greenblatt 2013-03-31 Reduce-0.17%$39.24 - $57.96
($50.79)
$ 93.9485%Reduce -94.2%4,660
CELGRay Dalio 2013-03-31 Sold Out -0.07%$39.24 - $57.96
($50.79)
$ 93.9485%Sold Out0
CELGJoel Greenblatt 2012-12-31 Add0.16%$35.65 - $41.04
($38.7)
$ 93.94143%Add 989.15%80,314
CELGMario Gabelli 2012-12-31 Add$35.65 - $41.04
($38.7)
$ 93.94143%Add 68.37%17,510
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CELG is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
CELG George Soros 2014-06-30688,0000.090.45New Buy
CELG Joel Greenblatt 2014-06-3063,9800.010.07New Buy
CELG Mario Gabelli 2014-06-3023,12000.01+7.34%
CELG Ronald Muhlenkamp 2014-06-30144,1400.022.2-51.74%
CELG Ray Dalio 2014-06-30000Sold Out
CELG John Burbank 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


CELG: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KAPLAN GILLADirector 2014-09-08Sell30,000$93.731.6view
LOUGHLIN JAMES JDirector 2014-08-22Sell20,000$91.254.36view
CASEY MICHAEL DDirector 2014-08-14Sell30,000$88.597.5view
KARSEN PERRY Asee remarks 2014-08-04Sell39,104$87.558.77view
BARKER RICHARD WDirector 2014-07-25Sell17,600$87.039.42view
Celgene International Inc10% Owner 2014-07-08Buy200,000$10852.3view
KAPLAN GILLADirector 2014-06-09Sell30,000$80.8117.84view
CELGENE CORP /DE/10% Owner 2014-05-05Buy1,100,000$42.86122.19view
KARSEN PERRY Asee remarks 2014-05-01Sell23,844$73.3929.76view
Celgene European Investment Co10% Owner 2014-04-29Buy294,800$44116.43view

Press Releases about CELG :

Quarterly/Annual Reports about CELG:

News about celg:

Articles On GuruFocus.com
Ken Fisher's Top Increases of the First Quarter Apr 22 2014 
David Winters' 2013 Letter to Wintergreen Fund Shareholders Mar 05 2014 
You Can No Longer Ignore Biotech Feb 07 2014 
Trying to Beat the Market Is a Fool’s Errand Oct 17 2013 
Insiders Are Buying Idera Pharmaceuticals Sep 19 2013 
comment on CELG Mar 20 2013 
Growth Stocks: There Is a Lot of Value in this Market Part 2 Sep 27 2012 
High frowth cheap in Jun 30 2012 
52-Week High Companies: CVS, TSM, PM, ROST, CELG Feb 27 2012 
52-Week High Companies: CELG, MON, ECL, SBUX, NWSA Jan 16 2012 

More From Our Partners
Celgene Corporation Shares Could Head Higher Sep 30 2014 - BENZINGA

More From Other Websites
Celgene And Sanofi CEOs Among Headliners For Third Forbes Healthcare Summit Sep 30 2014
Celgene Corporation Shares Could Head Higher Sep 30 2014
Five Reasons Celgene Could Gain 20% Sep 29 2014
Agios' Early Drug-Trial Report Cheers Wall Street Sep 26 2014
Today's Market Thorns, Roses, and All Time Highs... Plus an Extra... Sep 25 2014
Stocks Get Hit Hard; GoPro, Skechers Buck Weakness Sep 25 2014
Tech swoon: Apple leads decline Sep 25 2014
Apple Fuels Tech Sell-Off; Valeant Bucks The Trend Sep 25 2014
[video] Cramer's favorite large cap biotech plays Sep 24 2014
Celgene's Otezla Label Expanded to Include Plaque Psoriasis Sep 24 2014
Stocks Rally To Session Highs; Celgene Leads Biotech Rally Sep 24 2014
Jim Cramer's Mad Dash: Celgene and Morgan Stanley Still Have Upside Sep 24 2014
Cramer's Mad Dash: CELG going higher Sep 24 2014
Celgene's Sep 23 2014
Celgene's psoriasis drug gets approval for new indication Sep 23 2014
Celgene Wins U.S. Approval of New Psoriasis Pill Sep 23 2014
Oral OTEZLA® (apremilast) Approved by the U.S. Food and Drug Administration for the Treatment of... Sep 23 2014
Zeldes Haeggquist & Eck, LLP Announces Investigation of Celgene, Inc. Sep 22 2014
Nasdaq Touches 52-Week High; Concur Soars On Buyout Sep 19 2014
Celgene Appoints Tuomo Pätsi as President of EMEA and Commits to Continue Delivering Innovative... Sep 19 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK